Modulation of protein-protein interactions by stabilizing/mimicking protein secondary structure elements.
暂无分享,去创建一个
Mercedes Martín-Martínez | M. Martín-Martínez | M. J. P. de Vega | R. González-Muñiz | Maria Jesús Pérez de Vega | Rosario González-Muñiz
[1] D. Selkoe,et al. Alzheimer's Disease--Genotypes, Phenotype, and Treatments , 1997, Science.
[2] L. Vassilev,et al. Targeting protein–protein interactions for cancer therapy , 2005, Journal of Molecular Medicine.
[3] K. Gehring,et al. Solution Structure and Internal Motion of a Bioactive Peptide Derived from Nerve Growth Factor* , 1998, The Journal of Biological Chemistry.
[4] T. Barrette,et al. Probabilistic model of the human protein-protein interaction network , 2005, Nature Biotechnology.
[5] Dajun Yang,et al. Macrocyclization in the design of non-phosphorus-containing Grb2 SH2 domain-binding ligands. , 2004, Journal of medicinal chemistry.
[6] K. Burgess,et al. New templates for syntheses of ring-fused, C(10) beta-turn peptidomimetics leading to the first reported small-molecule mimic of neurotrophin-3. , 2002, Journal of medicinal chemistry.
[7] M. Schwaiger,et al. Carbohydrate Derivatives for Use in Drug Design: Cyclicαv-Selective RGD Peptides , 2000 .
[8] Bernhard Pfeiffer,et al. Over One Hundred Peptide‐Activated G Protein‐Coupled Receptors Recognize Ligands with Turn Structure , 2005 .
[9] Yong Wang,et al. Helix-stabilized cyclic peptides as selective inhibitors of steroid receptor–coactivator interactions , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[10] R. Liskamp. Conformationally Restricted Amino Acids and Dipeptides, (non) Peptidomimetics and Secondary Structure Mimetics , 1994 .
[11] J. Urban,et al. Sculpted immunogens; B-cell epitope optimization using constrained secondary structure libraries. , 1996, Bioorganic & medicinal chemistry.
[12] Shaomeng Wang,et al. Structure-based design, synthesis, and evaluation of conformationally constrained mimetics of the second mitochondria-derived activator of caspase that target the X-linked inhibitor of apoptosis protein/caspase-9 interaction site. , 2004, Journal of medicinal chemistry.
[13] Michael G. C. Kahn. Peptide Secondary Structure Mimetics: Recent Advances and Future Challenges , 1993 .
[14] D. Potenza,et al. Targeting integrins: insights into structure and activity of cyclic RGD pentapeptide mimics containing azabicycloalkane amino acids. , 2006, Bioorganic & medicinal chemistry.
[15] Joshua A. Kritzer,et al. Solution Structure of a β-Peptide Ligand for hDM2 , 2005 .
[16] Shibo Jiang,et al. Design of a protein surface antagonist based on alpha-helix mimicry: inhibition of gp41 assembly and viral fusion. , 2002, Angewandte Chemie.
[17] D. Selkoe. Alzheimer's disease: genotypes, phenotypes, and treatments. , 1997, Science.
[18] Wei Yang,et al. Small molecule integrin antagonists that bind to the beta2 subunit I-like domain and activate signals in one direction and block them in the other. , 2003, Immunity.
[19] Y. Pommier,et al. Interfacial inhibition of macromolecular interactions: nature's paradigm for drug discovery. , 2005, Trends in pharmacological sciences.
[20] G. Verdine,et al. An All-Hydrocarbon Cross-Linking System for Enhancing the Helicity and Metabolic Stability of Peptides , 2000 .
[21] Horst Kessler,et al. N-methylated cyclic RGD peptides as highly active and selective αvβ3 integrin antagonists , 1999 .
[22] Gabriel Lopez-Berestein,et al. Growth inhibition of breast cancer cells by Grb2 downregulation is correlated with inactivation of mitogen-activated protein kinase in EGFR, but not in ErbB2, cells , 1999, Oncogene.
[23] T Ueda,et al. A novel anti-HIV synthetic peptide, T-22 ([Tyr5,12,Lys7]-polyphemusin II). , 1992, Biochemical and biophysical research communications.
[24] Jean Chmielewski,et al. Inhibiting protein-protein interactions using designed molecules. , 2005, Current opinion in structural biology.
[25] Dajun Yang,et al. A novel macrocyclic tetrapeptide mimetic that exhibits low-picomolar Grb2 SH2 domain-binding affinity. , 2003, Biochemical and biophysical research communications.
[26] Robert J Fisher,et al. Examination of phosphoryl-mimicking functionalities within a macrocyclic Grb2 SH2 domain-binding platform. , 2005, Journal of medicinal chemistry.
[27] D. Whitcomb. Acute pancreatitis: Molecular biology update , 2003, Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract.
[28] Arun K. Ghosh,et al. Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors. , 2005, Journal of medicinal chemistry.
[29] B. Gibbs,et al. Small Peptide Mimics of Nerve Growth Factor Bind TrkA Receptors and Affect Biological Responses (*) , 1995, The Journal of Biological Chemistry.
[30] A. Cuello,et al. A designed peptidomimetic agonistic ligand of TrkA nerve growth factor receptors. , 2000, Molecular pharmacology.
[31] Edgar Jacoby,et al. Biphenyls as potential mimetics of protein α-helix , 2002 .
[32] C. E. Peishoff,et al. Potent, selective, orally active 3-oxo-1,4-benzodiazepine GPIIb/IIIa integrin antagonists. , 1996, Journal of medicinal chemistry.
[33] A. Levine,et al. Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain , 1996, Science.
[34] Razvan C. Bunescu,et al. Consolidating the set of known human protein-protein interactions in preparation for large-scale mapping of the human interactome , 2005, Genome Biology.
[35] John A. Robinson,et al. A virosome-mimotope approach to synthetic vaccine design and optimization: synthesis, conformation, and immune recognition of a potential malaria-vaccine candidate. , 2003, Angewandte Chemie.
[36] T. Fan,et al. Caspase family proteases and apoptosis. , 2005, Acta biochimica et biophysica Sinica.
[37] M. Manthorpe,et al. Synthetic NGF peptide derivatives prevent neuronal death via a p75 receptor‐dependent mechanism , 1997, Journal of neuroscience research.
[38] P. Alewood,et al. Conformational constraints: nonpeptide beta-turn mimics. , 1990, Journal of Molecular Recognition.
[39] P. Roller,et al. Global optimization of conformational constraint on non-phosphorylated cyclic peptide antagonists of the Grb2-SH2 domain. , 2003, Bioorganic & medicinal chemistry.
[40] Joshua A. Kritzer,et al. β-Peptides as inhibitors of protein–protein interactions , 2005 .
[41] K. Mayo,et al. Designed beta-sheet-forming peptide 33mers with potent human bactericidal/permeability increasing protein-like bactericidal and endotoxin neutralizing activities. , 1998, Biochimica et biophysica acta.
[42] Do-Hyoung Kim,et al. Proteomimetic libraries: design, synthesis, and evaluation of p53-MDM2 interaction inhibitors. , 2006, Journal of combinatorial chemistry.
[43] J. Nicholas,et al. Small molecule antagonists of proteins. , 2003, Biochemical pharmacology.
[44] D. Fairlie,et al. Proteases universally recognize beta strands in their active sites. , 2005, Chemical reviews.
[45] John A. Robinson,et al. A New Family of β‐Hairpin Mimetics Based on a Trypsin Inhibitor from Sunflower Seeds , 2002, Chembiochem : a European journal of chemical biology.
[46] T. Springer,et al. A dimeric crystal structure for the N-terminal two domains of intercellular adhesion molecule-1. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[47] D. Fairlie,et al. Beta-strand mimicking macrocyclic amino acids: templates for protease inhibitors with antiviral activity. , 2002, Journal of medicinal chemistry.
[48] H. Willems,et al. The design of dipeptide helical mimetics: the synthesis, tachykinin receptor affinity and conformational analysis of 1,1,6-trisubstituted indanes. , 1996, Bioorganic & medicinal chemistry.
[49] J. Osbourn,et al. Human antibodies by design , 1998, Nature Biotechnology.
[50] Shaomeng Wang,et al. Structure-based design of potent, conformationally constrained Smac mimetics. , 2004, Journal of the American Chemical Society.
[51] Shaomeng Wang,et al. Chimeric (α/β + α)-Peptide Ligands for the BH3-Recognition Cleft of Bcl-xL: Critical Role of the Molecular Scaffold in Protein Surface Recognition , 2005 .
[52] Antagonists of the Src homology 2 (SH2) domains of Grb2, Src, Lck and ZAP-70. , 2001, Current medicinal chemistry.
[53] C. E. Peishoff,et al. Design and synthesis of a C7 mimetic for the predicted gamma-turn conformation found in several constrained RGD antagonists. , 1992, Journal of medicinal chemistry.
[54] M. García-López,et al. 2(S)-amino-3-oxo-11b(R)-hexahydroindolizino[8,7-b]indole-5(S)-carboxylate as a new type of β-turn dipeptide mimetic , 1994 .
[55] D. Kohda,et al. A comparative study of the solution structures of tachyplesin I and a novel anti-HIV synthetic peptide, T22 ([Tyr5,12, Lys7]-polyphemusin II), determined by nuclear magnetic resonance. , 1993, Biochimica et biophysica acta.
[56] V. Madison,et al. Synthesis and biological activity of macrocyclic inhibitors of hepatitis C virus (HCV) NS3 protease. , 2005, Bioorganic & medicinal chemistry letters.
[57] T. Tomaszek,et al. A novel constrained reduced-amide inhibitor of HIV-1 protease derived from the sequential incorporation of gamma-turn mimetics into a model substrate. , 1993, Journal of medicinal chemistry.
[58] R. W. Hoffmann,et al. Designed beta-turn mimic based on the allylic-strain concept: Evaluation of structural and biological features by incorporation into a cyclic RGD peptide (cyclo(-L-arginylglycyl-L-α-aspartyl-)) , 2002 .
[59] H. Kim,et al. A Merger of Rational Drug Design and Combinatorial Chemistry: Development and Application of Peptide Secondary Structure Mimetics , 2001 .
[60] R. Nussinov,et al. Protein–protein interactions: Structurally conserved residues distinguish between binding sites and exposed protein surfaces , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[61] Selective formation of homo- and heterobivalent peptidomimetics. , 2003, Journal of medicinal chemistry.
[62] Dajun Yang,et al. Synthesis of a C-terminally biotinylated macrocyclic peptide mimetic exhibiting high Grb2 SH2 domain-binding affinity. , 2005, Bioorganic & medicinal chemistry.
[63] Joshua A. Kritzer,et al. Helical β-Peptide Inhibitors of the p53-hDM2 Interaction , 2004 .
[64] Youmei Xie,et al. Nerve Growth Factor (NGF) Loop 4 Dimeric Mimetics Activate ERK and AKT and Promote NGF-like Neurotrophic Effects* , 2000, The Journal of Biological Chemistry.
[65] Baoguang Zhao,et al. Structure activity relationships of 5-, 6-, and 7-methyl-substituted azepan-3-one cathepsin K inhibitors. , 2006, Journal of medicinal chemistry.
[66] Ulrich Hommel,et al. Small Molecule Inhibitors Induce Conformational Changes in the I Domain and the I-like Domain of Lymphocyte Function-associated Antigen-1 , 2002, The Journal of Biological Chemistry.
[67] H. Hauser,et al. β‐Peptides as Inhibitors of Small‐Intestinal Cholesterol and Fat Absorption , 1999 .
[68] John A. Robinson,et al. Properties and structure-activity studies of cyclic beta-hairpin peptidomimetics based on the cationic antimicrobial peptide protegrin I. , 2005, Bioorganic & medicinal chemistry.
[69] K. Burgess,et al. Molecular basis of neurotrophin-receptor interactions. , 2003, Journal of medicinal chemistry.
[70] D. Mochly‐Rosen,et al. Peptide modulators of protein–protein interactions in intracellular signaling , 1998, Nature Biotechnology.
[71] K. Satyshur,et al. Novel Cyclic Biphenyl Ether Peptide β-Strand Mimetics and HIV-Protease Inhibitors , 1997 .
[72] L. Presta,et al. Generation of an LFA-1 antagonist by the transfer of the ICAM-1 immunoregulatory epitope to a small molecule. , 2002, Science.
[73] P. Darke,et al. Design and synthesis of peptidomimetic inhibitors of HIV-1 protease and renin. Evidence for improved transport. , 1994, Journal of medicinal chemistry.
[74] John A. Robinson,et al. Structural mimicry of retroviral tat proteins by constrained beta-hairpin peptidomimetics: ligands with high affinity and selectivity for viral TAR RNA regulatory elements. , 2004, Journal of the American Chemical Society.
[75] J. Clemente,et al. Synthesis of malarial plasmepsin inhibitors and prediction of binding modes by molecular dynamics simulations. , 2005, Journal of medicinal chemistry.
[76] H. Kessler,et al. Conformational Analysis of a Cyclic RGD Peptide Containing a .psi.[CH2-NH] Bond: A Positional Shift in Backbone Structure Caused by a Single Dipeptide Mimetic , 1994 .
[77] Oliver Zerbe,et al. Using a β‐Hairpin To Mimic an α‐Helix: Cyclic Peptidomimetic Inhibitors of the p53–HDM2 Protein–Protein Interaction , 2004 .
[78] A. Hamilton,et al. Diphenylindane-based proteomimetics reproduce the projection of the i, i+3, i+4, and i+7 residues on an alpha-helix. , 2006, Organic letters.
[79] Giorgio Palù,et al. Protein–protein interactions as targets for antiviral chemotherapy , 2002, Reviews in medical virology.
[80] X Zhang,et al. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. , 1998, Biochemical and biophysical research communications.
[81] G. McGaughey,et al. HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAb. , 2003, Biochemistry.
[82] K. Abromeit. Music Received , 2023, Notes.
[83] D. Weiner,et al. Design and synthesis of a CD4 beta-turn mimetic that inhibits human immunodeficiency virus envelope glycoprotein gp120 binding and infection of human lymphocytes. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[84] H. Lehrach,et al. A Human Protein-Protein Interaction Network: A Resource for Annotating the Proteome , 2005, Cell.
[85] K. Burgess,et al. Dimeric β-turn peptidomimetics as ligands for the neurotrophin receptor TrkC , 2001 .
[86] D. Erdmann,et al. Structural basis for specificity of GRB2-SH2 revealed by a novel ligand binding mode , 1996, Nature Structural Biology.
[87] Paramjit S. Arora,et al. A highly stable short α-helix constrained by a main-chain hydrogen-bond surrogate , 2004 .
[88] A. D. de Vos,et al. Nerve growth factor: structure and function , 2001, Cellular and Molecular Life Sciences CMLS.
[89] D. Krag,et al. Nonphosphorylated Peptide Ligands for the Grb2 Src Homology 2 Domain* , 1997, The Journal of Biological Chemistry.
[90] D. Fairlie,et al. Macrocycles mimic the extended peptide conformation recognized by aspartic, serine, cysteine and metallo proteases. , 2001, Current medicinal chemistry.
[91] W. V. van Gunsteren,et al. Dynamical studies of peptide motifs in the Plasmodium falciparum circumsporozoite surface protein by restrained and unrestrained MD simulations. , 1997, Journal of molecular biology.
[92] Terry Walsh,et al. Countering cooperative effects in protease inhibitors using constrained beta-strand-mimicking templates in focused combinatorial libraries. , 2004, Journal of medicinal chemistry.
[93] Z. Yao,et al. Inhibition of angiogenesis by growth factor receptor bound protein 2-Src homology 2 domain bound antagonists. , 2004, Molecular cancer therapeutics.
[94] H. Kessler,et al. Synthesis and Structure−Activity Relationship of Mannose-Based Peptidomimetics Selectively Blocking Integrin α4β7 Binding to Mucosal Addressin Cell Adhesion Molecule-1 , 2003 .
[95] S. Sebti,et al. Terephthalamide derivatives as mimetics of helical peptides: disruption of the Bcl-x(L)/Bak interaction. , 2005, Journal of the American Chemical Society.
[96] John W. Bean,et al. Direct design of a potent non-peptide fibrinogen receptor antagonist based on the structure and conformation of a highly constrained cyclic RGD peptide , 1993 .
[97] Alexander D. MacKerell,et al. Identification of non-phosphate-containing small molecular weight inhibitors of the tyrosine kinase p56 Lck SH2 domain via in silico screening against the pY + 3 binding site. , 2004, Journal of medicinal chemistry.
[98] A. Griffioen,et al. Design of a Partial Peptide Mimetic of Anginex with Antiangiogenic and Anticancer Activity* , 2003, Journal of Biological Chemistry.
[99] C. E. Peishoff,et al. Conformations of Arg-Gly-Asp containing heterodetic cyclic peptides: solution and crystal studies , 1992 .
[100] Dale L Boger,et al. Solution-phase combinatorial libraries: modulating cellular signaling by targeting protein-protein or protein-DNA interactions. , 2003, Angewandte Chemie.
[101] Michael Loran Dustin,et al. The arrangement of the immunoglobulin-like domains of ICAM-1 and the binding sites for LFA-1 and rhinovirus , 1990, Cell.
[102] J. Martin,et al. Molecular recognition of macrocyclic peptidomimetic inhibitors by HIV-1 protease. , 1999, Biochemistry.
[103] A. Hamilton,et al. Terephthalamide derivatives as mimetics of the helical region of Bak peptide target Bcl-xL protein. , 2004, Bioorganic & medicinal chemistry letters.
[104] Brian W. Metcalf,et al. Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues , 1990, Nature.
[105] M. Zacharias,et al. Accounting for global protein deformability during protein-protein and protein-ligand docking. , 2005, Biochimica et biophysica acta.
[106] Yan-Li Song,et al. Binding affinity difference induced by the stereochemistry of the sulfoxide bridge of the cyclic peptide inhibitors of Grb2-SH2 domain: NMR studies for the structural origin. , 2005, Biochemical and biophysical research communications.
[107] Sibylle Ziegler,et al. Noninvasive Imaging of αvβ3 Integrin Expression Using 18F-labeled RGD-containing Glycopeptide and Positron Emission Tomography , 2001 .
[108] N. Yao,et al. Potent 7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid-based macrocyclic inhibitors of hepatitis C virus NS3 protease. , 2006, Journal of medicinal chemistry.
[109] T. Burke,et al. Macrocyclization in the design of a conformationally constrained Grb2 SH2 domain inhibitor. , 2001, Bioorganic & medicinal chemistry letters.
[110] S. Willis,et al. Life in the balance: how BH3-only proteins induce apoptosis. , 2005, Current opinion in cell biology.
[111] J. Thornton,et al. Diversity of protein–protein interactions , 2003, The EMBO journal.
[112] Jorge Becerril,et al. Design and application of an alpha-helix-mimetic scaffold based on an oligoamide-foldamer strategy: antagonism of the Bak BH3/Bcl-xL complex. , 2003, Angewandte Chemie.
[113] Ziwei Huang,et al. The chemical biology of apoptosis. Exploring protein-protein interactions and the life and death of cells with small molecules. , 2002, Chemistry & biology.
[114] P. Furet,et al. Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53. , 2000, Journal of medicinal chemistry.
[115] P. Toogood. Inhibition of protein-protein association by small molecules: approaches and progress. , 2002, Journal of medicinal chemistry.
[116] Steven Fletcher,et al. Protein surface recognition and proteomimetics: mimics of protein surface structure and function. , 2005, Current opinion in chemical biology.
[117] A. Hamilton,et al. Toward proteomimetics: terphenyl derivatives as structural and functional mimics of extended regions of an alpha-helix. , 2001, Journal of the American Chemical Society.
[118] S. Vasavanonda,et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[119] J. Matthews,et al. Protein-protein interactions in human disease. , 2005, Current opinion in structural biology.
[120] Ho-il Choi,et al. Synthesis of Irreversible HIV-1 Protease Inhibitors Containing Sulfonamide and Sulfone as Amide Bond Isosteres. , 1998 .
[121] G. Rose,et al. Hydrogen‐bonded turns in proteins: The case for a recount , 2005, Protein science : a publication of the Protein Society.
[122] Andrew D. Hamilton,et al. Terphenyl-Based Bak BH3 α-Helical Proteomimetics as Low-Molecular-Weight Antagonists of Bcl-xL , 2005 .
[123] S. Agarwal,et al. Design and modular parallel synthesis of a MCR derived alpha-helix mimetic protein-protein interaction inhibitor scaffold. , 2006, Bioorganic & medicinal chemistry letters.
[124] A. Hamilton,et al. Peptide and protein recognition by designed molecules. , 2000, Chemical reviews.
[125] B. M. Jimenez,et al. IBTM-Containing Gramicidin S Analogues: Evidence for IBTM as a Suitable Type II‘ β-Turn Mimetic1,2 , 1997 .
[126] S. Bodary,et al. Competition between intercellular adhesion molecule‐1 and a small‐molecule antagonist for a common binding site on the αl subunit of lymphocyte function‐associated antigen‐1 , 2006, Protein science : a publication of the Protein Society.
[127] A. Otaka,et al. Pharmacophore identification of a chemokine receptor (CXCR4) antagonist, T22 ([Tyr(5,12),Lys7]-polyphemusin II), which specifically blocks T cell-line-tropic HIV-1 infection. , 1998, Bioorganic & medicinal chemistry.
[128] Harold P. Erickson,et al. 2.0 Å Crystal Structure of a Four-Domain Segment of Human Fibronectin Encompassing the RGD Loop and Synergy Region , 1996, Cell.
[129] L. Presta,et al. Identification of the binding site in intercellular adhesion molecule 1 for its receptor, leukocyte function-associated antigen 1. , 1997, Molecular biology of the cell.
[130] Zhen-Dan Shi,et al. Crystal structures of a high-affinity macrocyclic peptide mimetic in complex with the Grb2 SH2 domain. , 2005, Journal of molecular biology.
[131] G. Rose,et al. Turns in peptides and proteins. , 1985, Advances in protein chemistry.
[132] D. Potenza,et al. Potent integrin antagonists from a small library of RGD-including cyclic pseudopeptides. , 2001, Organic letters.
[133] A. Hamilton,et al. Strategies for targeting protein-protein interactions with synthetic agents. , 2005, Angewandte Chemie.
[134] T. Hugli. Protease inhibitors: novel therapeutic application and development. , 1996, Trends in biotechnology.
[135] W. Delano. Unraveling hot spots in binding interfaces: progress and challenges. , 2002, Current opinion in structural biology.
[136] G. Milne,et al. Potent inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands. , 1999, Journal of medicinal chemistry.
[137] K. Burgess,et al. Syntheses and Activities of New C10 β-Turn Peptidomimetics , 2004 .
[138] A. Griffioen,et al. Designed β-sheet peptides that inhibit proliferation and induce apoptosis in endothelial cells , 2004, Angiogenesis.
[139] S. Korsmeyer,et al. Activation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 Helix , 2004, Science.
[140] Oliver Zerbe,et al. Structure–Activity Studies in a Family of β‐Hairpin Protein Epitope Mimetic Inhibitors of the p53–HDM2 Protein–Protein Interaction , 2006 .
[141] M. Martín-Martínez,et al. PACAP27 Analogues Incorporating Type II/II’ β-Turn Mimetics , 2001 .
[142] Horst Kessler,et al. Cyclic RGD Peptides Containing β-Turn Mimetics , 1996 .
[143] E Ruoslahti,et al. Solution structures and integrin binding activities of an RGD peptide with two isomers. , 2001, Biochemistry.
[144] D. Rees,et al. The synthesis of 1,6-disubstituted indanes which mimic the orientation of amino acid side-chains in a protein alpha-helix motif. , 1992 .
[145] P. Arora,et al. Enhanced metabolic stability and protein-binding properties of artificial alpha helices derived from a hydrogen-bond surrogate: application to Bcl-xL. , 2005, Angewandte Chemie.
[146] A. Otaka,et al. Downsizing of an HIV-cell fusion inhibitor, T22 ([Tyr5,12, Lys7]-polyphemusin II), with the maintenance of anti-HIV activity and solution structure. , 1998, Bioorganic & medicinal chemistry.
[147] H. S. Struijker Boudier,et al. Anginex, a designed peptide that inhibits angiogenesis. , 2001, The Biochemical journal.
[148] Kristian Rother,et al. Matching organic libraries with protein-substructures , 2001, J. Comput. Aided Mol. Des..
[149] Thilo Stehle,et al. Crystal Structure of the Extracellular Segment of Integrin αVβ3 in Complex with an Arg-Gly-Asp Ligand , 2002, Science.
[150] Stephen Hanessian,et al. Design and synthesis of conformationally constrained amino acids as versatile scaffolds and peptide mimetics , 1997 .
[151] D. Fairlie,et al. Beta-strand mimetics. , 2004, Chemical reviews.
[152] K. Burgess,et al. Long-Lasting Rescue of Age-Associated Deficits in Cognition and the CNS Cholinergic Phenotype by a Partial Agonist Peptidomimetic Ligand of TrkA , 2004, The Journal of Neuroscience.
[153] K. Burgess,et al. Ring closure to beta-turn mimics via copper-catalyzed azide/alkyne cycloadditions. , 2005, The Journal of organic chemistry.
[154] Timothy A. Springer,et al. Therapeutic antagonists and conformational regulation of integrin function , 2003, Nature Reviews Drug Discovery.
[155] P. Lewi,et al. Protein–protein interactions: mechanisms and modification by drugs , 2002, Journal of molecular recognition : JMR.
[156] K. Gehring,et al. Design and solution structure of functional peptide mimetics of nerve growth factor. , 2000, Journal of medicinal chemistry.
[157] P. Furet,et al. Structure-based design and synthesis of high affinity tripeptide ligands of the Grb2-SH2 domain. , 1998, Journal of medicinal chemistry.
[158] W. Delano,et al. Convergent solutions to binding at a protein-protein interface. , 2000, Science.
[159] Giorgio Palù,et al. Disruption of protein–protein interactions: Towards new targets for chemotherapy , 2005, Journal of cellular physiology.
[160] Toshiaki Hara,et al. Probing the structural requirements of peptoids that inhibit HDM2-p53 interactions. , 2006, Journal of the American Chemical Society.
[161] J. Trent,et al. Stereoselective synthesis of [L-Arg-L/D-3-(2-naphthyl)alanine]-type (E)-alkene dipeptide isosteres and its application to the synthesis and biological evaluation of pseudopeptide analogues of the CXCR4 antagonist FC131. , 2005, Journal of medicinal chemistry.
[162] K. Gehring,et al. Development of pharmacological agents for targeting neurotrophins and their receptors. , 2000, Trends in pharmacological sciences.
[163] Thommey P. Thomas,et al. Tumor angiogenic vasculature targeting with PAMAM dendrimer-RGD conjugates. , 2005, Chemical communications.
[164] Vadim M Govorun,et al. Protein‐protein interactions as a target for drugs in proteomics , 2003, Proteomics.
[165] Stephen C Peiper,et al. Identification of novel low molecular weight CXCR4 antagonists by structural tuning of cyclic tetrapeptide scaffolds. , 2005, Journal of medicinal chemistry.
[166] M. Shimaoka,et al. Intersubunit signal transmission in integrins by a receptor-like interaction with a pull spring. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[167] D. Fairlie,et al. Protease inhibitors: current status and future prospects. , 2000, Journal of medicinal chemistry.
[168] W. Bode,et al. A player of many parts: the spotlight falls on thrombin's structure. , 1993, Thrombosis research.
[169] John A. Robinson,et al. Structural Mimicry of Canonical Conformations in Antibody Hypervariable Loops Using Cyclic Peptides Containing a Heterochiral Diproline Template , 1999 .
[170] Structure Activity Relationships , 2005 .
[171] A. Griffioen,et al. Beta-sheet is the bioactive conformation of the anti-angiogenic anginex peptide. , 2003, The Biochemical journal.
[172] J. Nowick,et al. Designed Molecules That Fold to Mimic Protein Secondary Structures , 2000 .
[173] Lin Hong,et al. Structure-based design of cycloamide–urethane-derived novel inhibitors of human brain memapsin 2 (β-secretase) , 2005 .
[174] S. Sebti,et al. Protein – Protein Interactions Terphenyl-Based Helical Mimetics That Disrupt the p 53 / HDM 2 Interaction * * , 2007 .
[175] C. Dobson. Protein Folding and Disease: a view from the first Horizon Symposium , 2003, Nature Reviews Drug Discovery.
[176] K. Kitaura,et al. Stereoselective synthesis of 3,6-disubstituted-3,6-dihydropyridin-2-ones as potential diketopiperazine mimetics using organocopper-mediated anti-SN2' reactions and their use in the preparation of low-molecule CXCR4 antagonists. , 2006, The Journal of organic chemistry.
[177] K. Appelt,et al. Isophthalic acid derivatives: amino acid surrogates for the inhibition of HIV-1 protease , 1995 .
[178] R. Timpl,et al. Arg‐Gly‐Asp constrained within cyclic pentapoptides Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1 , 1991, FEBS letters.
[179] A. Otaka,et al. Effective lowly cytotoxic analogs of an HIV-cell fusion inhibitor, T22 ([Tyr5,12, Lys7]-polyphemusin II). , 1998, Bioorganic & medicinal chemistry.
[180] P. Chène. Inhibiting the p53–MDM2 interaction: an important target for cancer therapy , 2003, Nature Reviews Cancer.
[181] Mercedes Martín-Martínez,et al. Conformationally constrained CCK4 analogues incorporating IBTM and BTD beta-turn mimetics. , 2005, Journal of medicinal chemistry.
[182] C. Nguyên,et al. Chemogenomics with peptide secondary structure mimetics. , 2003, Combinatorial chemistry & high throughput screening.
[183] John A. Robinson,et al. Protein ligand design: from phage display to synthetic protein epitope mimetics in human antibody Fc-binding peptidomimetics. , 2006, Journal of the American Chemical Society.
[184] Jennifer L. Martin,et al. Regioselective Structural and Functional Mimicry of Peptides - Design of Hydrolytically-Stable Cyclic Peptidomimetic Inhibitors of Hiv-1 Protease , 1995 .
[185] T. Berg. Modulation of protein-protein interactions with small organic molecules. , 2003, Angewandte Chemie.
[186] Kazuya Machida,et al. The SH2 domain: versatile signaling module and pharmaceutical target. , 2005, Biochimica et biophysica acta.
[187] A. Cochran,et al. Protein-protein interfaces: mimics and inhibitors. , 2001, Current opinion in chemical biology.
[188] R. Linhardt,et al. Interaction of Secretory Leukocyte Protease Inhibitor with Heparin Inhibits Proteases Involved in Asthma* , 1998, The Journal of Biological Chemistry.
[189] Andrew D. Hamilton,et al. Synthesis of a 2,3‘;6‘,3‘ ‘-Terpyridine Scaffold as an α-Helix Mimetic , 2005 .
[190] Yoshua Bengio,et al. Selective small molecule peptidomimetic ligands of TrkC and TrkA receptors afford discrete or complete neurotrophic activities. , 2005, Chemistry & biology.
[191] Dajun Yang,et al. Development of a phosphatase-stable phosphotyrosyl mimetic suitably protected for the synthesis of high-affinity Grb2 SH2 domain-binding ligands. , 2002, Bioorganic & medicinal chemistry letters.
[192] Richard S Larson,et al. Design and structure of peptide and peptidomimetic antagonists of protein-protein interaction. , 2005, Current protein & peptide science.
[193] T. Aoki,et al. Design, synthesis, and structure-activity relationships of potent GPIIb/IIIa antagonists: discovery of FK419. , 2005, Bioorganic & medicinal chemistry.
[194] John A. Robinson,et al. Exploiting Conformationally Constrained Peptidomimetics and an Efficient Human‐Compatible Delivery System in Synthetic Vaccine Design , 2001, Chembiochem : a European journal of chemical biology.
[195] J. Clemente,et al. Macrocyclic inhibitors of the malarial aspartic proteases plasmepsin I, II, and IV. , 2006, Bioorganic & medicinal chemistry.
[196] R. Hughes,et al. Design of Potent Peptide Mimetics of Brain-derived Neurotrophic Factor* , 2003, Journal of Biological Chemistry.
[197] V. Chow,et al. Design, structure and biological activity of beta-turn peptides of CD2 protein for inhibition of T-cell adhesion. , 2004, European journal of biochemistry.
[198] Michelle Arkin,et al. Protein-protein interactions and cancer: small molecules going in for the kill. , 2005, Current opinion in chemical biology.
[199] D. Roberts,et al. Novel integrin antagonists derived from thrombospondins. , 2005, Current pharmaceutical design.
[200] Structure-activity relationships for macrocyclic peptidomimetic inhibitors of HIV-1 protease , 1996 .
[201] Helen E Blackwell,et al. Highly Efficient Synthesis of Covalently Cross-Linked Peptide Helices by Ring-Closing Metathesis. , 1998, Angewandte Chemie.
[202] D. Fowlkes,et al. Peptide antagonists of the human estrogen receptor. , 1999, Science.
[203] C. E. Peishoff,et al. Discovery of Potent Nonpeptide Vitronectin Receptor (αVβ3) Antagonists , 1997 .
[204] Stephen Hanessian,et al. Structure-based design, synthesis, and memapsin 2 (BACE) inhibitory activity of carbocyclic and heterocyclic peptidomimetics. , 2005, Journal of medicinal chemistry.
[205] D. Fairlie,et al. Synthesis, stability, antiviral activity, and protease-bound structures of substrate-mimicking constrained macrocyclic inhibitors of HIV-1 protease. , 2000, Journal of medicinal chemistry.
[206] John A. Robinson,et al. Crystal structure of an NPNA-repeat motif from the circumsporozoite protein of the malaria parasite Plasmodium falciparum. , 2006, Chemical communications.
[207] Andrew D. Hamilton,et al. Development of a Potent Bcl-xL Antagonist Based on α-Helix Mimicry , 2002 .
[208] Jiandong Chen,et al. p53 α-Helix mimetics antagonize p53/MDM2 interaction and activate p53 , 2005, Molecular Cancer Therapeutics.
[209] Ronald Kühne,et al. Recognition of proline-rich motifs by protein-protein-interaction domains. , 2005, Angewandte Chemie.
[210] Dajun Yang,et al. Macrocyclization in the design of Grb2 SH2 domain-binding ligands exhibiting high potency in whole-cell systems. , 2003, Journal of medicinal chemistry.
[211] Teppei Ogawa,et al. Structure-activity relationship studies on CXCR4 antagonists having cyclic pentapeptide scaffolds. , 2005, Organic & biomolecular chemistry.